skip to main content
Guest
My Research
My Account
Sign out
Sign in
This feature requires javascript
Library Search
Find Databases
Browse Search
E-Journals A-Z
E-Books A-Z
Citation Linker
Help
Language:
English
Vietnamese
This feature required javascript
This feature requires javascript
Primo Search
All Library Resources
All
Course Materials
Course Materials
Search For:
Clear Search Box
Search in:
All Library Resources
Or hit Enter to replace search target
Or select another collection:
Search in:
All Library Resources
Search in:
Print Resources
Search in:
Digital Resources
Search in:
Online E-Resources
Advanced Search
Browse Search
This feature requires javascript
Search Limited to:
Search Limited to:
Resource type
criteria input
All items
Books
Articles
Images
Audio Visual
Maps
Graduate theses
Show Results with:
criteria input
that contain my query words
with my exact phrase
starts with
Show Results with:
Search type Index
criteria input
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
Show Results with:
in the title
Show Results with:
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
This feature requires javascript
The outcome of bevacizumab treatment for diabetic macular oedema at the Charlotte Maxeke Johannesburg Academic Hospital
Digital Resources/Online E-Resources
Citations
Cited by
View Online
Details
Recommendations
Reviews
Times Cited
External Links
This feature requires javascript
Actions
Add to My Research
Remove from My Research
E-mail
Print
Permalink
Citation
EasyBib
EndNote
RefWorks
Delicious
Export RIS
Export BibTeX
This feature requires javascript
Title:
The outcome of bevacizumab treatment for diabetic macular oedema at the Charlotte Maxeke Johannesburg Academic Hospital
Author:
Hasrod, Irfaan
Subjects:
Bevacizumab
;
Intravitreal Injections
;
Macular Edema
Description:
A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, in partial fulfilment of the requirements for the degree of Masters of Medicine in Ophthalmology, Johannesburg 2018 Aim: The aim of this study is to examine the outcomes of treatment of diabetic macular oedema using bevacizumab at Charlotte Maxeke Johannesburg Academic Hospital by analysing the change in visual acuity and a change in retinal macular thickness at three months following the first intravitreal bevacizumab injection. Method: A retrospective study of the records of all patients treated with intravitreal bevacizumab for diabetic macular oedema from 1st January 2013 to 31 December 2015 was done. Results: A total of 178 eyes (from 151 patients) were treated for diabetic macular oedema during the period of 1st January 2013 to 31st December 2015. Seventeen of these eyes were treated with 1 injection, 33 with 2 injections and 128 eyes with 3 injections from baseline to three months. From the patients who were treated with 3 injections, 80 completed treatment at three months and 48 went on to receive more injections. Thus dividing the eyes into 4 groups. Patients who received 1 injection showed no median change in VA, logMAR 1.0 interquartile range ”IQR” (0.6LogMAR; 2.0 LogMAR) at baseline to LogMAR 1.0 IQR (0.48logMAR; 2.0LogMAR) at three months. Patients who received 2 injections also showed no median change in VA, logMAR 0.77 IQR (0.6logMAR; 0.77logMAR) at baseline to logMAR 0.77 IQR (0.6logMAR; 1.0logMAR) at three months. Patients who received 3 injections showed an increase of visual acuity, LogMAR 0.77 IQR (0.6logMAR; 1.0logMAR) at baseline to logMAR 0.60 IQR (0.48logMAR; 0.77logMAR) at three months. The patients who received 3 injections at baseline and went on to receive further injections also showed an increase in median visual acuity, logMAR 0.77 IQR (LogMAR0.6; logMAR1.00) at baseline to logMAR 0.60 IQR (logMAR0.48; logMAR1.00) at three months. There was a decrease in macula thickness in all 4 groups. In patients receiving three injections at three months there was a significant p-value of 0.018 for thechange in macula thickeness from baseline of 313 micrometres IQR (256micrometres; 419micrometres) to three months of 266 micrometres IQR (219micrometres; 356micrometres). For patients who received three injections at three months but went on to receive further injections, a significant p-value of P=0.0061 for the change in macula thickness from baseline of 398 micrometres IQR (328micrometres; 452micrometres) to three months of 321 micrometres IQR (262micrometers; 387 micrometers). Conclusion: Bevacizumab is useful in the treatment of Diabetic macular oedema in terms of an increase in visual acuity and decrease in macular thickness, provided patients receive a loading dose of three intravitreal injections in the first three months of treatment. XL2019
Creation Date:
2018
Language:
English
Source:
WIReDSpace
This feature requires javascript
This feature requires javascript
Back to results list
This feature requires javascript
This feature requires javascript
Searching Remote Databases, Please Wait
Searching for
in
scope:(TDTS),scope:(SFX),scope:(TDT),scope:(SEN),primo_central_multiple_fe
Show me what you have so far
This feature requires javascript
This feature requires javascript